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ABSTRACT 
Phosphopeptides are valuable reagent probes for studying protein-protein and protein-ligand 
interactions. The cellular delivery of phosphopeptides is challenging because of the presence of 
the negatively charged phosphate group. The cellular uptake of a number of fluorescent-labeled 
phosphopeptides, including F′-GpYLPQTV, F′-NEpYTARQ, F′-AEEEIYGEFEAKKKK, F′-
PEpYLGLD, F′-pYVNVQN-NH2, and F′-GpYEEI (F′ = fluorescein) was evaluated in the 
presence or absence of a [WR]4, a cyclic peptide containing alternative arginine (R) and 
tryptophan (W) residues, in human leukemia cells (CCRF-CEM) after 2 h incubation using flow 
cytometry. [WR]4 improved significantly the cellular uptake of all phosphopeptides. PEpYLGLD 
is a sequence that mimics the pTyr1246 of ErbB2 that is responsible for binding to the Chk SH2 
domain. The cellular uptake of F′-PEpYLGLD was enhanced dramatically by 27-fold in the 
presence of [WR]4 and was found to be time-dependent. Confocal microscopy of a mixture of F′-
PEpYLGLD and [WR]4 in live cells exhibited intracellular localization and significantly higher 
cellular uptake compared to that of F′-PEpYLGLD alone. Transmission electron microscopy 
(TEM) and Isothermal Calorimetric (ITC) were used to study the interaction of PEpYLGLD and 
[WR]4. TEM results showed that the mixture of PEpYLGLD and [WR]4 formed noncircular 
nanosized structures with width and height of 125 and 60 nm, respectively. ITC binding studies 
confirmed the interaction between [WR]4 and PEpYLGLD. The binding isotherm curves, 
derived from sequential binding models, showed an exothermic interaction driven by entropy. 
These studies suggest that amphiphilic peptide [WR]4 can be used as a cellular delivery tool of 
cell-impermeable negatively charged phosphopeptides. 
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Introduction 
Peptide amphiphiles (PAs) are composed of a combination of amino acids carrying 
hydrophobic/hydrophilic and positively/negatively charged residues.1 PAs have been found to be 
promising tools in drug and gene delivery due to their biocompatibility and bioactivity.2-4 These 
compounds are not toxic to cells at their experimental concentration and are able to cross the cell 
membrane because of their unique structural properties.  
Hydrophobic unit of PAs can contain long chain fatty acids or amino acids with 
hydrophobic side chain residues. This unit generates a pocket that could be responsible for the 
entrapment of drugs and facilitates the internalization into the cell membrane.5 At the same time, 
the presence of positively charged arginine facilitates the interaction between the peptide and the 
negatively charged phospholipids on the cell membrane. The application of positively charged 
linear cell-penetrating peptides (CPPs) as drug carriers for biologically active cargos has been 
reported previously.6-9 Polyarginines, TAT (trans-acting activator of transcription), and 
Penetratin have been found to enhance the cellular uptake of a diverse range of drugs.10-12 Thus, 
the appropriate combination of amino acids in the structure of peptide determines the efficiency 
and function of the delivery system.  
Phosphopeptides are valuable reagent probes mimicking phosphoproteins for studying 
protein-protein and protein-ligand interactions13,14 and determination of substrate specificity of 
the Src homology 2 (SH2) domain,15 phosphatases,16,17 and phosphotyrosine binding (PTB) 
domains.18,19 The use of phosphopeptides has been challenging due to the fact that they have 
limited cellular uptake because of the presence of the negatively charged phosphate group. 
Several chemical modifications have been used to enhance the intracellular delivery of 
phosphopetides through covalent conjugation to other transporter peptides.20-22 These strategies 
suffer from several disadvantages including multistep synthesis of the fusion conjugates, low 
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loading yields, and the requirement of cleavage through chemical or enzymatic reactions to 
release phosphopeptides.23  
Peptidomimetic prodrugs have been reported for intracellular delivery of aryl 
phosphoramidates24 and difluoromethyl phosphonates25. Arrendale and co-workers developed a 
(difluoromethylene)phosphoserine prodrug to deliver negatively charged phosphoserine 
peptidomimetic intracellularly. FOXO3a is a transcription factor that is phosphorylated by Akt1 
and binds to 14-3-3-adaptor protein. The released modified phosphopeptide was able to release 
FOXO3a from 14-3-3 protein, leading to cell death in leukemia cells.26,27 Other phosphoserine 
and phosphothreonine masked phosphopeptides have been evaluated in studying kinase 
regulation.28,29 
Considering the critical roles of the phosphopeptides in cellular signaling pathways, we 
have previously reported amphiphilic linear peptide analogues to improve the intracellular 
uptake of negatively charged phosphopeptides through noncovalent conjugation.30 The linear 
positively charged peptides were designed based on the Src SH2 domain phosphotyrosine (pTyr) 
binding pocket.  
We introduced a new class of homochiral cyclic peptides containing arginine (R) and 
tryptophan (W) such as [WR]4 that were appropriate carriers for a wide range of drugs.31 This 
system showed that the optimized balance between positive charge and hydrophobicity was 
critical for the peptide to enhance the intracellular delivery of drugs through interaction with the 
cell membrane and penetration into the lipid bilayer. Cyclic [WR]4 provided major advantages 
compared to their linear counterparts, including higher enzymatic stability, bypassing endosomal 
uptake, improved cell permeability, and nuclear targeting.31  
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In continuation of our efforts to introduce new applications of [WR]4 for the delivery of 
biomolecules, we report here using [WR]4 for improving the cellular delivery of negatively 
charge phosphopeptides. Addition of negatively charged phosphopeptides to the positively 
charged [WR]4 led to the formation of nanostructures through intermolecular interactions. To the 
best of our knowledge, this is the first report of using a cell-penetrating cyclic peptide for cellular 
delivery of impermeable phosphopeptides. 
 
Experimental Section 
General 
All amino acids were purchased from Chem-Impex International, Inc. HBTU was purchased 
from Oakwood products, Inc. All other chemicals and reagents were purchased from Sigma-
Aldrich Chemical Co. (Milwaukee, WI). The chemical structures of final products were 
confirmed by high-resolution MALDI AXIMA performance TOF/TOF mass spectrometer 
(Shimadzu Biotech). Details of procedures and spectroscopic data of the respective compounds 
are presented below. Final compounds were purified on a Phenomenex Prodigy 10 µm ODS 
reversed-phase column (2.1 cm × 25 cm) with a Hitachi HPLC system using a gradient system of 
acetonitrile (CH3CN) or methanol and water (CH3OH/H2O) (0−100%, pH 7.0, 60 min). The 
purity of final products (≥95%) was confirmed by analytical HPLC. The analytical HPLC was 
performed on a Hitachi analytical HPLC system using a C18 Shimadzu Premier 3 µm column 
(150 cm × 4.6 mm) and a gradient system (water/CH3CN), and a flow rate of 1 mL/min with 
detection at 220 nm. Cyclic peptide [WR]4 was synthesized according to our previously reported 
procedure.31 As representative examples, the synthesis of Ac-PEpYLGLD and F′-PEpYLGLD is 
outlined here. 
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Synthesis of Ac-PE(pY)LGLD and F′-PE(pY)LGLD. Side chain protected peptide 
PE(pY)LGLD was assembled on Fmoc-Asp(OtBu)-Wang resin (740 mg, 0.54 mmol/g, 0.4 
mmol) by solid-phase peptide synthesis strategy using Fmoc-protected amino acids [Fmoc-Leu-
OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Tyr(PO3tBu2)-OH, Fmoc-Glu(OtBu)-OH, and Fmoc-
Pro-OH] on a PS3 automated peptide synthesizer at room temperature using 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and N-
methylmorpholine (NMM, 0.4 M) in N,N-dimethylformamide (DMF) as coupling and activating 
agents, respectively (Scheme 1). After the assembly of the side chain protected peptide sequence, 
the Fmoc protecting group at the N-terminal proline was removed using piperidine in DMF (20% 
v/v). The resin was washed with DCM (3 × 15 mL) and MeOH (3 × 15 mL) for further 
modification using either capping reagent (acetic anhydride) or fluorescein labeling reagent 
(5(6)-carboxyfluorescein isobutyrate). The resin was dried overnight under vacuum and divided 
into two parts. The capping reaction was carried out on the first portion using acetic anhydride 
((CH3CO)2O) (953 µL) and N,N-diisopropylethylamine (DIPEA) (1,742 µL) (50/50 equiv) in 
DMF (10 mL). The mixture containing peptide-attached resin and reagents was shaken for 30 
min, followed by washing with DMF (5 × 15 mL), DCM (5 × 15 mL), and MeOH (3 × 15 mL), 
respectively. The resin was dried under vacuum at room temperature for 24 h. The second 
portion of the resin was swelled in DMF (2 × 20 mL) for 2 h. The preactivation reaction was 
performed on the fluorescein reagent using a mixture of 5(6)-carboxyfluorescein isobutyrate (5 
equiv), 1-hydroxy-7-azabenzotriazole (HOAt, 5 equiv)/7-azabenzotriazol-1-yloxy 
tripyrrolidinophosphonium hexafluorophosphate) (PyAOP, 5 equiv)/DIPEA, 10 equiv) in 
DMF:DCM (5:1 v/v, 12 mL) for 10 min. The activated fluorescein reagent was added to the 
peptide-attached resin and stirred at room temperature for 3 h. After the completion of the 
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reaction, the resin was washed by DMF (5 × 15 mL), DCM (3 × 15 mL), and MeOH (5 × 15 
mL), respectively. The protecting group (isobutyrate) was removed from the carboxyfluorescein 
by treating the peptide-attached resin with 20% piperidine in DMF (5 × 15 mL, 25 min each). 
Finally, the resin was washed with DMF (5 × 15 mL), DCM (5 × 15 mL), and MeOH (5 × 15 
mL), respectively, followed by drying under a high vacuum at room temperature for 24 h. The 
cleavage reagent R cocktail containing trifluoroacetic acid (TFA)/thioanisole/ethandithiol 
(EDT)/anisole (90:5:3:2 v/v/v/v, 12 mL) was added to both portions of the resin, and the 
mixtures were stirred at room temperature for 2 h. The resins were filtered and washed with 
Reagent R (2 mL) again. The filtrates were evaporated to reduce the volume under dry nitrogen. 
The crude peptides were precipitated by adding cold diethyl ether (200 mL, Et2O) and 
centrifuged at 4000 rpm for 5 min, followed by decantation to obtain the solid precipitates. The 
solid materials were further washed with cold ether (2 × 100 mL) for 2 times. The peptides were 
lyophilized and purified by reversed-phase Hitachi HPLC (L-2455) on a Phenomenex Prodigy 10 
µm ODS reversed-phase column (2.1 cm × 25 cm) using a gradient system to yield the linear 
capped Ac-PE(pY)LGLD and fluorescein-labeled F′-PE(pY)LGLD peptides, respectively. 
Similarly, other fluorescein-labeled peptides were synthesized according to this procedure. 
Ac-PE(pY)LGLD (shown here as PE(pY)LGLD). MALDI-TOF (m/z) [C39H58N7NaO17P]: 
calcd [M + Na]+, 950.3524; found, 950.3524. 
F′-PE(pY)LGLD. MALDI-TOF (m/z) [C58H67N7O22P]: calcd [M + H]+, 1244.4077; found, 
1244.4080, [C58H66N7NaO22P]: calcd [M + Na]+, 1266.3896; found, 1266.3899. 
F′-G(pY)LPQTV. MALDI-TOF (m/z) [C57H67N8NaO20P]: calcd [M + Na]+, 1237.4107; found, 
1237.4108; [C57H67KN8O20P]: calcd [M + K]+, 1253.3846; found, 1253.3846.  
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F′-NE(pY)TARQ. MALDI-TOF (m/z) [C57H68N12O23P]: calcd [M + H]+, 1319.4258; found, 
1319.4258. 
F′-AEEEI(pY)GEFEAKKKK. MALDI-TOF (m/z) [C102H139N19O36P]: calcd [M + H]+, 
2236.9368; found, 2236.9370.  
F′-PS(pY)VNVQN-NH2. MALDI-TOF (m/z) [C61H74N12O22P]: calcd [M + H]+, 1357.4778; 
found, 1357.4781. 
F′-G(pY)EEI. MALDI-TOF (m/z) [C48H51N5O20P]: calcd [M+ H]+, 1048.2865; found, 
1048.2872. 
 
Cell Culture and Cytotoxicity Assay 
Cell Culture. Human leukemia carcinoma cell line CCRF-CEM (ATCC No. CCL-119), ovarian 
adenocarcinoma SK-OV-3 (ATCC No. HTB-77), colorectal carcinoma HCT-116 (ATCC No. 
CCL-247), and normal human colon myofibroblast (CCD-18Co, ATCC No. CRL-1459) were 
obtained from American Type Culture Collection. Cells were grown in 75 cm2 cell culture flasks 
with EMEM (Eagle’s minimum essential medium), supplemented with 10% fetal bovine serum, 
and 1% penicillin/streptomycin solution (10,000 units of penicillin and 10 mg of streptomycin in 
0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37 ºC. 
 
Flow Cytometry Studies. Human leukemia adenocarcinoma (CCRF-CEM, 1 × 107 cells) or 
human ovarian adenocarcinoma cells (SK-OV-3, 3 × 105cells) were taken in 6-well plates in 
opti-MEM or serum-free RPMI medium. Then the fluorescence-labeled phosphopeptides (F′-
PE(pY)LGLD, F′-G(pY)LPQTV, F′-NE(pY)TARQ, F′-PS(pY)VNVQN-NH2, F′-
AEEEI(pY)GEFEAKKKK, or F′-G(pY)EEI) (5-10 µM) were added to the different wells 
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containing [WR]4 (25-50 µM) in medium. The plates were incubated for 1-2 h at 37 °C. Cells 
and fluorescence-labeled phosphopeptides alone were used as negative controls. After 1-2 h 
incubation, the media containing the peptide was removed. The cells were digested with 0.25% 
trypsin/EDTA (0.53 mM) for 5 min to remove any artificial surface binding. Then the cells were 
washed twice with PBS. Finally, the cells were resuspended in flow cytometry buffer and 
analyzed by flow cytometry (FACSCalibur: Becton Dickinson) using FITC channel and 
CellQuest software. The data presented were based on the mean fluorescence signal for 10,000 
cells collected. All assays were performed in triplicate. A similar procedure was used for linear 
(WR)4 and linear tripodal peptide LPA4 FACS studies.  
 
Cell Cytotoxicity Assay of [WR]4 + PEpYLGLD Mixture. SK-OV-3 (5,000 cells), CCRF-
CEM (40,000 cells), HCT-116 (4,000), and CCD-18Co (3,000 cells) were seeded in 0.1 ml per 
well in 96-well plates 24 h prior to the experiment. The old medium (EMEM containing fetal 
bovine serum (FBS) (10%) for SK-OV-3, HCT-116 and CCD-18Co was removed. The stock 
solutions were prepared at high concentrations to generate maximum intermolecular interactions 
and then were diluted to desired concentrations for cellular studies. [WR]4 (25 µM) + 
PEpYLGLD (5 µM) or [WR]4 (50 µM) + PEpYLGLD (10 µM) in serum containing medium was 
added, and the cells were incubated for 24 h at 37 °C in a humidified atmosphere of 5% CO2. In 
the case of CCRF-CEM (nonadherent cells), the final concentration was calculated after addition 
of the compounds. Cell viability was then determined by measuring the fluorescence intensity of 
the formazan product at 490 nm using a SpectraMax M2 microplate spectrophotometer. The 
percentage of cell survival was calculated as [(OD value of cells treated with the test mixture of 
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compounds - OD value of culture medium)]/[(OD value of control cells - OD value of culture 
medium)] × 100%. 
 
Cellular Uptake Studies in the Presence of Inhibitors. Human ovarian adenocarcinoma cells 
(SK-OV-3) were seeded in 6-well plates (3 × 105 cells/well) in opti-MEM. The cells were 
preincubated by various inhibitors including nystatin (50 µg/ml), chloroquine (100 µM), 
chlorpromazine (30 µM), methyl-β-cyclodextrin (2.5 mM), and 5-(N-ethyl-N-
isopropyl)amiloride (EIA, 50 µM) for 30 min. The treatment was removed, and the cells were 
incubated with [WR]4 (25 µM), F′-PE(pY)LGLD (5 µM), and a similar concentration of 
inhibitors for 1 h. To induce ATP depletion, the cells were preicubated with 0.5% of 150 mM 
sodium azide in opti-MEM prior to the addition of the compound followed by 1 h incuabtion. 
Consequently, a similar FACS protocol was performed as described above.  
 
Confocal Microscopy on Live Cells. Adherent SK-OV-3 cells were seeded with EMEM media 
overnight on coverslips in 6-well plates. Then the media were removed and washed with opti-
MEM. The cells were treated with F′-PEpYLGLD (5 µM) in the presence or absence of [WR]4 
(25 µM) for 1 h at 37 ºC. The stock solutions were prepared at high concentrations to generate 
maximum intermolecular interactions and then were diluted to desired concentrations for cellular 
studies. After 1 h incubation, the media containing the treatments were removed followed by 
washing with PBS three times. Then the coverslips were mounted on a microscope slide with 
mounting media with the cell-attached side facing down. Laser scanning confocal microscopy 
was carried out using Carl Zeiss LSM 510 system. The cells were imaged using FITC and phase 
contrast channels.  
13 
 
 
Transmission Electron Microscopy (TEM). TEM samples were prepared by drop casting of 
PEpYLGLD (1 mM in H2O), [WR]4 (1 mM in H2O), or mixture of PEpYLGLD and [WR]4 (1 
mM in H2O) solution (incubated for one day) (10 µL) onto the Formvar coated carbon grid of 
mesh size 300, which was allowed to sit for 2 min. Excess solvent was carefully removed by 
capillary action (filter paper). Grids were allowed to dry at room temperature for overnight. All 
images were taken using JEOL transmission electron microscope (Tokyo, Japan) maintained at 
80 kv. After drop casting of peptide solutions, grids were then stained with uranyl acetate (20 
µL) for 2 min. Excess stain was removed, and the grids were allowed to dry overnight.  
 
Isothermal Titration Calorimetry (ITC). ITC was performed on a Microcal VP-ITC 
microcalorimeter (Microcal, Northampton, MA). Data acquisition and instrument control were 
carried out using a dedicated Origin software package. All the experiments were performed at 30 
°C using cyclic peptide [WR]4 (100 µM) and PEpYLGLD (5 mM). Both PEpYLGLD and [WR]4 
were dissolved in water. A solution
 
containing [WR]4 (1.42 mL) was transferred into the sample 
cell. A solution of PEpYLGLD (5 mM, 10 µL) was injected from the syringe (280 µL) into the 
stirred sample cell (stirring speed 307 rpm). The reference cell was filled with deionized water. 
A 180 s time interval between injections was applied in order to allow the system to reach 
thermal equilibrium after each addition. Corrections were made for the dilution heat of the 
phosphopeptide, which was determined in control experiments under similar conditions. 
Analysis of the integrated heat data was performed using the Origin 7 package provided with the 
ITC instrument. Experimental data was fitted using a nonlinear least-squares minimization 
algorithm to a theoretical titration curve. Different binding models were assumed, involving a 
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single set of identical sites, two sets of independent sites, or sequential binding events. The 
equations were included in the commercial ITC Data analysis software package of Origin 7.0. 
The chi-square parameter χ2 was used to establish the best fit. 
 
Circular Dichroism. CD spectra were recorded on a JASCO J-810 spectropolarimeter using 1 
mm path length cuvettes. The scan speed was 100 nm/min, and spectra were averaged over 8 
scans. All experiments on the samples including [WR]4 (25 µM, H2O) and PEpYLGLD (25 µM, 
H2O) were tested at room temperature. The CD for background reference (water) was measured 
and subtracted from the sample. 
 
Molecular Modeling. Initial coordinates for [WR]5 were obtained using GAUSSVIEW.32 Ab 
initio Hartree Fock molecular orbital calculations with complete geometry optimizations were 
performed with 6-31G33 basis set on monomer [WR]5 utilizing GAUSSIAN’03 software. 
Geometry of monomers was completely optimized. All bond lengths, bond angles and dihedral 
angles were allowed to relax without any constraint. 
 
RESULTS AND DISCUSSION 
Chemistry 
A number of fluorescence labeled phosphopeptides, F′-GpYLPQTV, F′-NEpYTARQ, F′-
AEEEIYGEFEAKKKK, F′-PEpYLGLD, F′-pYVNVQN-NH2, and F′-GpYEEI, where F′ is 
fluorescein (Figure 1) were synthesized including according to the previously reported 
procedure.34 These phosphopeptides were selected based on the sequence of phosphoprotein 
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binding motif of protein tyrosine kinases that binds to the SH2 domain of other protein tyrosine 
kinases and leads to enzyme activation.35  
 
Figure 1. Chemical structure of [WR]4 and phosphopeptides synthesized by Fmoc-based peptide 
chemistry.  
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As representative examples, the synthesis of Ac-PEpYLGLD (mentioned here as 
PEpYLGLD) and F′-PEpYLGLD is outlined here (Scheme 1). In general, the peptides were 
assembled on Wang resin using Fmoc solid-phase synthesis. Fmoc protection group at the N-
terminal was removed. Subsequent capping reaction by acetic anhydride or conjugation reaction 
with 5(6)-carboxyfluorescein isobutyrate was performed in the presence of HOAt, PyAOP, and 
N,N-diisopropylethylamine (DIPEA) in DMF:DCM (5:1 v/v) followed by deprotection, and 
cleavage from the resin in the presence of reagent R containing TFA/thioanisole/EDT/anisole 
(90:5:3:2 v/v/v/v) afforded crude products, which were purified by preparative reversed-phase 
HPLC. The structures of the compounds were confirmed by high-resolution MALDI TOF/TOF 
and/or high-resolution electrospray mass spectrometry. We have previously reported the 
synthesis of [WR]4.31 A similar procedure was employed for the synthesis of other 
phosphopeptides by using appropriate resins and side chain protected amino acids. 
 
17 
 
 
Scheme 1. Solid-Phase Synthesis of Ac-PE(pY)LGLD and F′-PE(pY)LGLD. 
 
Cellular Uptake Studies 
The cellular uptake of synthesized fluorescence-labeled phosphopeptides (10 µM) was 
examined in the presence and absence of [WR]4 (50 µM) in human leukemia carcinoma (CCRF-
CEM) cells after 2 h incubation at 37 oC using flow cytometry. After the incubation, cells were 
treated with trypsin to remove the cell surface-bound compound. [WR]4 enhanced the cellular 
uptake of all phosphopeptides, including F′-GpYLPQTV, F′-NEpYTARQ, F′-
AEEEIYGEFEAKKKK, F′-pYVNVQN-NH2, and F′-GpYEEI by 7-, 5-, 10-, 4-, and 19-fold, 
respectively. Fluorescence-activated cell sorting (FACS) analysis showed that the cellular uptake 
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of F′-PEpYLGLD in the presence of [WR]4 was increased dramatically by 27-fold when 
compared to F′-PEpYLGLD alone (Figure 2). These data indicate that the cellular uptake of the 
phosphopeptides was improved in the presence of [WR]4 in a sequence dependent manner 
possibly due to different binding affinity between the phosphopeptides and [WR]4. 
Figure 2. Comparative cellular uptake of F′-phosphopeptides (10 µM) in the presence of [WR]4 
(50 µM) in CCRF-CEM cells after 2 h. 
 
Because of dramatic effect of [WR]4 on improving the cellular delivery of F′-
PEpYLGLD, this phosphopeptide was selected for further studies. PEpYLGLD is a sequence 
that mimics the pTyr1246 of ErbB2 that is responsible binding to the Chk SH2 domain.14 The 
cellular uptake of F′-PEpYLGLD (10 µM) was also evaluated in the presence of the linear (WR)4 
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(50 µM) using FACS under similar conditions and compared with that of cyclic [WR]4 (Figure 
3). The results showed that the linear (WR)4 enhanced the cellular uptake of F′-PEpYLGLD by 
17-fold in CCRF-CEM cells after 1 h incubation. However, the cyclic [WR]4 was found to 
enhance the cellular uptake of F′-PEpYLGLD approximately 24-fold after 1 h incubation under 
similar conditions, suggesting the cyclic nature of the peptide is important for improving the 
cellular delivery of the phosphopeptide. 
We have previously reported that Lys-(CH2)11-Arg-(CH2)11-Arg, a linear tripodal 
amphipathic peptide containing two arginine and one lysine residues (LPA4), enhanced the 
cellular delivery of a phosphopeptide (F′-GpYEEI) in the human breast carcinoma cells BT-20 
(ATCC no. HTB-19) cells by 10-fold.30 A comparative FACS study exhibited that the cellular 
uptake of F′-PEpYLGLD (10 µM) enhanced approximately 6 times in the presence of LP4 (50 
µM) in CCRF-CEM cells after 1 h incubation. Thus, the transporting efficiency of LPA4 for F′-
PEpYLGLD was significantly less than that of the cyclic [WR]4 that showed 24-fold higher 
cellular delivery of the same phosphopeptide after 1 h incubation (Figure 3). 
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Figure 3. Cellular uptake of F′-PEpYLGLD (10 µM) in the presence of cyclic [WR]4 (50 µM), 
linear (WR)4 (50 µM), or a tripodal linear peptide (LP4) (50 µM) in CCRF-CEM cells after 1 h 
incubation. 
 
To evaluate the cytotoxicity of PEpYLGLD and [WR]4, cell viability assay was employed 
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h incubation at 37 °C (Figure 4). While [WR]4 (25 µM) and PEpYLGLD (5 µM) did not exhibit 
any cytotoxicity in SK-OV-3 and CCRF-CEM cells, the mixture showed 10-12% toxicity when 
higher concentrations of phosphopeptide (10 µM) and [WR]4 (50 µM) were used. Thus, a 
concentration of PEpYLGLD (5 µM) and [WR]4 (25 µM) was used in SK-OV-3 and CCRF-
CEM cells in all cellular uptake and confocal microscopy studies.  
  
Figure 4. Cytotoxicity assay of the mixture of PEpYLGLD (5 and 10 µM) and [WR]4 (25 and 50 
µM) in CCRF-CEM, HCT-116, SK-OV-3, and CCD-18Co cells after 24 h. 
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The cellular uptake and internalization of many CPPs along with the conjugated cargo 
occurs predominantly via an endocytic pathway that involves macropinocytosis, caveolae 
pathway, clathrin-mediated endocytosis, or lipid-raft dependent endocytosis. The nature of the 
cell lines and the presence and type of the cargo could affect the specific mechanism employed 
by the CPP.36 We have previously shown that the cellular uptake of [WR]4 was independent of 
endocytosis.31a Thus, the mechanism of the cellular uptake of the complex mixture of [WR]4 and 
F′-PEpYLGLD was evaluated in the presence of different inhibitors to determine whether the 
cargo changes the uptake mechanism.  
To perform the ATP depletion, sodium azide was incubated with cells for 30 min prior to 
the incubation with the complex followed by 1 h incubation. Significant intracellular uptake of 
F′-PEpYLGLD in the presence of [WR]4 in SK-OV-3 cells (Figure 5a) was still observed in the 
presence of sodium azide, suggesting that the cellular uptake is not significantly reduced by 
inducing ATP depletion. 
Furthermore, [WR]4 was still able to improve the cellular uptake of F′-PEpYLGLD in 
SK-OV-3 cells in the presence of different endocytic inhibitors, such as nystatin, EIA, 
chlorpromazine, chloroquine, and methyl β-cyclodextrin ruling out clathrin-mediated or 
caveolae-mediated endocytosis, and macropinocytosis as the major mechanism of uptake after 1 
h incubation (Figure 5a). The cellular delivery of the phosphopeptide in the presence of [WR]4 
and inhibitors was still higher than F′-PEpYLGLD alone, suggesting the mechanism of cellular 
uptake is not exclusively endocytosis. This is a key advantage of [WR]4 compared to known 
CPPs, which are dependent on endocytotic entry. Another proposed mechanism for cellular 
uptake of CPPs is direct membrane transduction. The amphipathic nature of [WR]4 and 
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interactions of arginine and tryptophan residues in [WR]4 with the corresponding negatively 
charged phospholipids and hydrophobic residues in lipid bilayer may have contributed to the 
initial entry into the cell membrane. Hydrophobic interactions between tryptophan residues and 
the lipids could lead to possible distortion of the outer phospholipid monolayer, followed by 
peptide internalization and enhanced cellular uptake of the cargo. Model studies have suggested 
that the direct transduction occurs through carpetlike perturbations, pore formation, or inverted 
micelles formed in the bilayer membrane.36 Further mechanistic studies will provide insights for 
designing the next generation of cyclic peptides as molecular transporters of phosphopeptides. 
The cellular uptake of F′-PEpYLGLD was found to be rapid and time-dependent. F′-
PEpYLGLD (5 µM) was incubated with [WR]4 (25 µM) at different incubation times including 
10 min, 30 min, and 1 h. FACS results showed that the cellular uptake of F′-PEpYLGLD was 
increased in a time-dependent pattern (Figure 5b). On the other hand, the cellular uptake of F′-
PEpYLGLD was not changed significantly in the absence of [WR]4. 
24 
 
 
Figure 5. (a) Cellular uptake of F′-PEpYLGLD (5 µM) + WR]4 (25 µM) in the absence or 
presence of different endocytic inhibitors and sodium azide in SK-OV-3 cells after 1 h; (b) 
FACS analysis of cellular uptake assays of F′-PEpYLGLD (5 µM)-loaded [WR]4 (25 µM) 
compared to F′-PEpYLGLD (5 µM) alone in CCRF-CEM. 
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Confocal microscopy in live cells was used to monitor the cellular uptake of F′-
PEpYLGLD in the presence and absence of the peptide. Incubation of a mixture of F′-
PEpYLGLD [WR]4 showed significantly higher cellular uptake when compared to that of F′-
PEpYLGLD alone as shown by intracellular fluorescence. Comparison of the intracellular 
localization of F′-PEpYLGLD–loaded [WR]4 to F′-PEpYLGLD alone after 1 h incubation at 37 
°C confirmed that the presence of the cyclic peptide is critical for the enhanced cellular 
permeability (Figure 6). 
 
PEpYLGLD (5 µM) 
+ [WR]4 (25 µM)
PEpYLGLD (5 µM)
FITC Bright Field Merged
[WR] 4 (25 µM) 
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Figure 6. Confocal microscope images of F′-PEpYLGLD (5 µM) uptake by SK-OV-3 cells in 
the presence of [WR]4 (25 µM). 
Circular dichroism (CD), transmission electron microscopy (TEM), and isothermal 
titration calorimetry (ITC) were used to gain a better insight about the interaction of [WR]4 and 
PEpYLGLD. CD was used to get a better understanding of the secondary structure change in 
[WR]4 and PEpYLGLD upon mixing and intermolecular interactions. All spectra were corrected 
for background by subtraction of the blank. CD results showed that PEpYLGLD (25 µM) loaded 
with [WR]4 (25 µM) showed a different CD pattern compared to those of parent analogues, 
[WR]4 (25 µM) and PEpYLGLD (25 µM). While PEpYLGLD did not show any specific 
structure, both PEpYLGLD loaded [WR]4 and [WR]4 exhibited a maximum at 230 nm and a 
minimum at 203-205 nm, suggesting that [WR]4 maintain the secondary structure partially upon 
binding with in
 
PEpYLGLD. These secondary structures are distinct from known α and β 
structures. However, the pattern of the spectra shows some major differences between 
PEpYLGLD-loaded [WR]4 and [WR]4 at <190 nm and in intensity of ellipticity in maximum and 
minimum peaks (Figure 7).  
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Figure 7. CD pattern of PEpYLGLD and [WR]4 compared to the PEpYLGLD-loaded [WR]4. 
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through electrostatic and/or hydrophobic intermolecular interactions between the positively 
charged cyclic peptide and negatively charged phosphopeptide (Figure 8b). TEM images further 
confirm that the structures of [WR]4 modify upon binding with PEpYLGLD, generating new 
nanostructures.  
 
Figure 8. (a) Negatively stained TEM images of [WR]4 (1 mM), PEpYLGLD (1 mM), and 
PEpYLGLD-loaded [WR]4 (1 mM) in water after one day; (b) Proposed mechanism of 
interactions between PEpYLGLD  and [WR]4. 
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ITC was used to measure the binding constants between PEpYLGLD and [WR]4 in 
complex formation. The ITC measurements were carried out at 30 °C by adding an aqueous 
solution PEpYLGLD (6 mM) to [WR]4 (500 µM) solution in water. The equation for three 
sequential binding events was found to be the best fit for the data as shown by the Origin 
software. The chi squared χ2 value was found 1.6 × 102 produced by three sequential models. 
The binding constants values for three sequential events were determined K1 = 7.1 × 103 M-1, K2 
= 4.9 × 103 M-1, and K3= 1.1 × 104 M-1 (Figure 9). The enthalpies (∆H) for the binding were -
0.17, 0.30, and -0.23 kcal/mol, and the entropies (T∆S) were 5.2, 5.4, and 5.3 kcal/mol, 
respectively. Therefore, the Gibbs free energies (∆G) calculated from ∆H and T∆S were -5.4, -
5.1, and -5.6 kcal/mol for each binding site. ITC data suggest that PEpYLGLD and [WR]4 form a 
complex through multistep intermolecular interactions including hydrophobic interactions driven 
by entropy as shown previously.37 These data indicate that, in addition to the electrostatic 
interactions between positively charged cyclic peptide and negatively charged phosphopeptide, 
hydrophobic forces also contribute to the complex formation possibly due to the interactions of 
the hydrophobic tryptophan and leucine residues in [WR]4 and PEpYLGLD, respectively. ITC 
and TEM results are relevant to cellular studies since the stock solutions were prepared at high 
concentrations to generate maximum intermolecular interactions and then were diluted further to 
obtain desired concentration for cell-based assays. 
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Figure 9. The binding isotherm obtained from titration of PEpYLGLD (6 mM) with [WR]4 (500 
µM) using a three sequential-binding sites model.  
 
Molecular modeling studies of [WR]5, a similar model cyclic peptide, were used to gain 
better insights of three-dimensional structure of this class of peptides. Initial coordinates for 
[WR]5 were obtained followed by Ab initio Hartree Fock molecular orbital calculations with 
complete geometry optimizations utilizing GAUSSIAN’03 software.32 Two different 
conformations were obtained (Figure 10). The lowest energy conformation did not allow any 
intramolecular H-bonding. Higher energy conformation (25 kcal/mol) showed intramolecular H-
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bonding between cationic and neutral side chains. Side chains have to reorganize for efficient 
intramolecular H-bonding resulting in higher energy conformation. In the lowest energy 
conformation tryptophan side chains are disposed perpendicular to backbone. Higher energy 
conformation being more planar seems more suited for stacking.  
 
Figure 10. Two different conformers of [WR]5. 
 
Relative energy= 0.0 kCal/mol
Relative energy= 25.33 kCal/mol
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Conclusions 
In summary, a new carrier system for the delivery of cell impermeable phosphopeptides 
was discovered using cyclic octapeptide [WR]4 containing alternative tryptophan and arginine 
residues. The cellular uptake of F′-PEpYLGLD was enhanced by 27-fold in the presence of 
[WR]4, and was found to be time-dependent. Positively charged cyclic peptide formed 
nanostructures in the presence of negatively charged PEpYLGLD as shown by TEM. Binding 
affinity between [WR]4 and PEpYLGLD was further confirmed by ITC studies. To the best of 
our knowledge, this is the first report of using cyclic peptides for noncovalent cellular delivery of 
cell impermeable phosphopeptides. These data provide insights about using cell penetrating 
cyclic peptides as PAs for delivery of negatively charged cell impermeable phophopeptides.  
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ABBREVIATIONS 
BT-20, human breast carcinoma cell line; CCRF-CEM, human leukemia carcinoma cell line; 
CD, circular dichroism; CCD-18Co, normal human colon myofibroblast; CPPs, cell-penetrating 
peptides; DCM, dichloromethane; DIPEA, N,N-diisopropylethylamine; DMF N,N-
dimethylformamide; EIA, 5-(N-ethyl-N-isopropyl)amiloride; F′, fluorescein; FACS, fluorescence 
activated cell sorter; FBS, fetal bovine serum; DCM, dichloromethane; EDT, ethandithiol; 
HBTU, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HCT-116, 
human colorectal carcinoma; HOBt, hydroxybenzotriazole; HOAt, 1-hydroxy-7-
azabenzotriazole; ITC, isothermal calorimetric; NMM, N-methylmorpholine; PAs, peptide 
amphiphiles; PTB, phosphotyrosine binding; PyAOP, 7-azabenzotriazol-1-yloxy 
tripyrrolidinophosphonium hexafluorophosphate); SH2, Src homology 2; SK-OV-3, human 
ovarian adenocarcinoma; TFA, trifluoroacetic acid; TEM, transmission electron microscopy. 
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